Predictive biomarkers of colon cancer immunotherapy: Present and future

Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors (ICIs) have shown clinical benefits for colon cancer patients, especially those with high microsatellite instability (MSI-H). In 2020, the US Food and Drug Administration (FDA)-approved ICI pembrolizumab as the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Wanting, Yi, Cheng, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722772/
https://www.ncbi.nlm.nih.gov/pubmed/36483562
http://dx.doi.org/10.3389/fimmu.2022.1032314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722772/
https://www.ncbi.nlm.nih.gov/pubmed/36483562
http://dx.doi.org/10.3389/fimmu.2022.1032314

Ejemplares similares